TSE:4503Pharmaceuticals
Is Astellas Pharma (TSE:4503) Fairly Valued After Strong First Quarter 2026 Earnings?
Why Astellas Pharma’s Latest Earnings Matter For Investors
Astellas Pharma (TSE:4503) has drawn fresh attention after reporting first quarter 2026 earnings. Sales reached ¥640,914 million and net income was ¥141,828 million, compared with ¥505,794 million and ¥68,422 million a year earlier.
See our latest analysis for Astellas Pharma.
The first quarter report appears to have supported momentum in Astellas Pharma’s stock, with a 30 day share price return of 7.42% and a 1 year total shareholder...